Atossa Q3 2022: cash $117.5M, no revenue; FDA authorizes Phase 2 endoxifen study

ATOSSA THERAPEUTICS, INC.

Cash, cash equivalents and restricted cash $117.5M as of Sep 30, 2022; no revenue in Q3.
Operating expenses $8.2M in Q3 2022, up 59% YoY; R&D $5.2M (+134%) on higher trial costs.
FDA authorized Phase 2 neoadjuvant (Z)-endoxifen for ER+/HER2- breast cancer; enrollment expected Q4 2022.
Invested in privately-held Dynamic Cell Therapies (CAR-T); paid $300K for exclusive negotiation right.
Completed dosing in Parts B and C of Phase 1/2a AT-H201 trial for lung injury from cancer treatment.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ATOSSA THERAPEUTICS, INC. reported the fiscal quarter ended September 30, 2022 results: revenue no source of revenue.

Period: the fiscal quarter ended September 30, 2022
Revenue: no source of revenue
Result: reported results

Exact text from the filing

Atossa Therapeutics, Inc. (Nasdaq: ATOS), today announces financial results for the fiscal quarter ended September 30, 2022

View on SEC.gov

Browse all earnings releases →

ATOSSA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-22-026177

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.